Gli altri portali
Notizie a Confronto
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
MarketsandMarkets' 360Quadrants Recognizes Top Startups and SMEs in the Pharmacy…
Company Highlights in the Pharmacy Automation Startups/SMEs Companies Assessment: Company Highlights in the Pharmacy Automation Startups/SMEs Companies Assessment: To explore the full quadrant report and see how companies are positioned in the Pharmacy Automation Startups/SMEs Companies Assessment, 2025, Visit:https://www.360quadrants.com/healthcare/pharmacy-automation-startups Evaluation Criteria The vendor evaluation was conducted on over 70 companies, of which the...
PR Newswire
05/08/2025
Biomaterials Market to Grow at a CAGR of 15.5% from 2025 to 2032 | SkyQuest…
Get Free Sample Copy of the Report: https://www.skyquestt.com/sample-request/biomaterials-market Get Free Sample Copy of the Report:https://www.skyquestt.com/sample-request/biomaterials-market Biomaterials Market Key Growth Drivers The biomaterials market is experiencing robust growth driven by a convergence of factors that highlight the increasing demand for advanced medical solutions. One of the most prominent drivers is the rising global prevalence of chronic diseases, such as...
PR Newswire
05/08/2025
Cell Culture Market to Reach USD 71.1 Billion by 2032, Says SkyQuest Technology…
Get a Free Sample Report - https://www.skyquestt.com/sample-request/cell-culture-market Get a Free Sample Report -https://www.skyquestt.com/sample-request/cell-culture-market Cell Culture Market Key Growth Drivers Biopharmaceutical companies depend on advanced cell culture systems to produce safe and effective biologics. Use of monoclonal antibodies, vaccines, and recombinant proteins is rising rapidly around the world. As chronic diseases, cancers, and autoimmune disorders...
PR Newswire
05/08/2025
Liquid Biopsy Market worth US$7.05 billion by 2030 with 11.8% CAGR |…
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350 Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=13966350 Browse in-depth TOC on "Liquid Biopsy Market" 486 - Tables 60 - Figures 393 - Pages By technology,the liquid biopsy market is segmented by technology into multi-gene parallel analysis using NGS and single-gene analysis using PCR & microarrays. In 2024, the multi-gene parallel analysis using...
PR Newswire
05/08/2025
With 6.4% CAGR, Extracorporeal CO2 Removal Devices Market to Reach US$184.36…
Extracorporeal CO₂ removal systems are primarily utilized in critical care involving patients with acute respiratory failure and COPD. Extracorporeal CO₂ removal devices allow clinicians to undertake lower-set ventilator parameters and diminish ventilator-induced lung injuries. Extracorporeal CO₂ removal systems are primarily utilized in critical care involving patients with acute respiratory failure and COPD. Extracorporeal CO₂ removal devices allow clinicians to undertake lower-set…
PR Newswire
05/08/2025
Topical Drug Delivery Market US$409.0 Billion Forecast by 2030 with 8.8% CAGR |…
Browse in-depth TOC on "Topical Drug Delivery Market" Browse in-depth TOC on "Topical Drug Delivery Market" 468 - Tables 71 - Figures 435 - Pages By product,the topical drug delivery market is segmented into semi-solid formulations, liquid formulations, solid formulations, transdermal products, and other products. Other products include stick, aerosol (spray), and foam. The large share of the semi-solid formulations segment is attributed to its convenience and ease of...
PR Newswire
05/08/2025
Cardiovascular Echocardiography Market is Expected to Reach US$222.14 Million by…
The cardiovascular echocardiography market analysis focuses on advancements such as 3D/4D echocardiography, strain imaging, and AI-powered diagnostic tools. These advancements are expected to play a vital role in the market growth in the coming years. The report runs an in-depth analysis of market trends, key players, and future opportunities. The cardiovascular echocardiography market analysis focuses on advancements such as3D/4D echocardiography , strain imaging ,and AI-powered...
PR Newswire
05/08/2025
Seegene Unveils CURECA™ and STAgora™ at ADLM 2025, Advancing the Next Stage of…
"With CURECA™ and STAgora™, we are taking an important step toward the future of diagnostics," said Dr. Jong-Yoon Chun, Chairman and CEO of Seegene, during a press conference with U.S. and global media on July 30. "Our goal is to enable laboratories worldwide to automate complex testing workflows and use diagnostic data more effectively, ultimately helping advance global efforts toward a world free from diseases." "With CURECA™ and STAgora™, we are taking an important…
PR Newswire
05/08/2025
Tecan schedules conference call on August 12th to discuss half year 2025…
Männedorf, Switzerland, August 5, 2025 –The Tecan Group AG (SIX Swiss Exchange: TECN) will hold a conference call to discuss the financial results for the first half year 2025 on Tuesday, August 12th, 2025 at 08:30 CEST. The results will be published on August 12th, 2025 at 6:00 CEST.The conference call will be audio-webcast with synchronized presentation slides. The webcast and a replay of the webcast will be made available in the "Investor Relations" section of Tecan's websitewww...
Nasdaq GlobeNewswire
05/08/2025
Court Sides with Cardiovalve in Edwards patent spat
Case Background Case Background The dispute centered on Edwards' challenge to the validity of Cardiovalve's U.S. Patent No. 10,702,385 ("'385 Patent") covering an innovative transcatheter heart valve clamping and support structure for minimally invasive mitral and tricuspid valve therapies. OnJune 2, 2021, Edwards petitioned for inter partes review of claims 1-10 of that patent. PTAB issued Final Written Decision allowing Cardiovalve's motion to amend claims after Edwards failed...
PR Newswire
05/08/2025
AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate…
AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate UpdateThree active immunotherapies for precision prevention of neurodegeneration progressing through Phase 2 clinical developmentACI-7104.056 anti-alpha-synuclein active immunotherapy in Parkinson’s disease produced strong immunogenicity and favorable safety profile in interim results from the ongoing Phase 2 VacSYn reported in April, with further data to come in H2 2025Third Alzheimer’s disease cohort...
Nasdaq GlobeNewswire
05/08/2025
MoonLake Immunotherapeutics Reports Second Quarter 2025 Financial Results and…
Phase 3 VELA program in hidradenitis suppurativa (HS) on track for an expected primary endpoint readout around September 2025 and an expected submission of a Biologic License Application (BLA) in the United States in mid-2026Other clinical trials of sonelokimab in palmoplantar pustulosis (PPP), axial spondyloarthritis (axSpA), psoriatic arthritis (PsA) and adolescent HS progressing well and expected to support a catalyst-rich roadmap over the next 12 monthsEnded the second quarter with $425...
Nasdaq GlobeNewswire
05/08/2025
SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve…
"We are proud to deepen our partnership with AstraZeneca through this significant new initiative, which highlights the growing demand for secure, compliant, and scalable real-world AI applications," said Ross Muken, President of SOPHiA GENETICS. "Our platform is purpose-built to manage complex healthcare data environments, and this collaboration reinforces our shared commitment to driving better patient outcomes through trusted, federated analytics powered by data and AI."…
PR Newswire
05/08/2025
ZINZINO AB (PUBL.): PRELIMINARY SALES REPORT JULY 2025
Accumulated revenue for January – July 2025 increased by 57 % to SEK 1,780.1 (1,130.7) million. Accumulated revenue for January –July 2025increased by 57 % toSEK 1,780.1(1,130.7) million. Revenues were distributed as follows: Countries in regions: -The Nordics:Denmark, Faroe Island,Finland,Iceland,Norway,Sweden- Central Europe :Austria,Germany,Switzerland- East Europe :Czech Republic,Slovakia,Hungary,Poland,Romania-South &West...
PR Newswire
05/08/2025
Trailhead Biosystems Expands iPSC-Derived Portfolio with TrailBio® Hematopoietic…
Designed for applications such as hematopoietic disease modeling, drug screening and hematotoxicity studies, TrailBio® Hematopoietic Progenitor Cells enable a reliable human model system that eliminates donor variability and supports reproducible results. Designed for applications such as hematopoietic disease modeling, drug screening and hematotoxicity studies, TrailBio ®Hematopoietic Progenitor Cells enable a reliable human model system that eliminates donor variability and supports...
PR Newswire
05/08/2025
LA ROCHE-POSAY AND GLOBAL SKIN HEALTH EXPERTS UNITE TO WARN ABOUT LONG TERM…
LA ROCHE-POSAY REAFFIRMS ITS LONGSTANDING COMMITMENT TO SKIN HEALTHAs a global leader in sun protection and skin cancer prevention, La Roche-Posay is worried about the long-term consequences of the Burn Lines challenge and aims at warning the public of how dangerous this practice can be, alongside health professionals. LA ROCHE-POSAY REAFFIRMS ITS LONGSTANDING COMMITMENT TO SKIN HEALTHAs a global leader in sun protection and skin cancer prevention, La Roche-Posay is worried about the...
PR Newswire
05/08/2025
Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial…
First patient in Phase I/II clinical trial expected to be enrolled in Q4 2025UK Clinical Trial Application (CTA) approval shortly follows U.S. IND clearance and granting of European Medicine Agency (EMA) orphan drug designation, enabling readiness for initiation across sites in both the U.S. and EuropePS-002, Purespring’s lead precision nephrology programme, targets the complement pathway known to be a driver of IgA nephropathy and is supported by a wealth of preclinical dataLondon...
Nasdaq GlobeNewswire
05/08/2025
Nicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan
Press ReleaseNicox’s Partner Kowa Initiates NCX 470 Phase 3 Clinical Trial in Japan Exclusive Japanese partner Kowa has initiated a Phase 3 safety clinical trial of NCX 470 for the treatment of ocular hypertension in JapanTriggers a €2 million milestone payment to Nicox August 5, 2025 – release at 7:30 am CET Sophia Antipolis, France Nicox SA(Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that its exclusive...
Nasdaq GlobeNewswire
05/08/2025
Kuros Biosciences launches MagnetOs MIS Delivery System by completing first…
Kuros Biosciences launches MagnetOs MIS Delivery System by completing first cases, and continues global expansion with incremental Brazil clearanceSchlieren (Zürich), Switzerland, August 5, 2025– Kuros Biosciences (“Kuros” or the “Company”) a leader in innovative biologic technologies, today announced the completion of the first U.S. cases using the new MagnetOs TMMIS Delivery System – a sterile, prefilled, single-use delivery system engineered for Minimally Invasive Surgery...
Nasdaq GlobeNewswire
05/08/2025
Interstitial Cystitis Market to Grow Rapidly at a CAGR of 4% During the Study…
Key Takeaways from the Interstitial Cystitis Market Report Key Takeaways from the Interstitial Cystitis Market Report Discover which therapies are expected to grab the major interstitial cystitis drugs market share @Interstitial Cystitis Market Report Interstitial Cystitis Overview Interstitial cystitis, also known as bladder pain syndrome, is a chronic condition characterized by persistent bladder pressure, pain, and sometimes pelvic discomfort. The exact cause of...
PR Newswire
04/08/2025
Cellectis Reports Second Quarter 2025 Financial Results & Business Updates
Cellectis to host an Investor R&D Day in New York City on October 16, 2025: Phase 1 dataset and late-stage development strategy for lasme-cel (UCART22) in r/r B-ALL to be presented End-of-Phase 1 meetings with FDA & EMA for lasme-cel (UCART22) in r/r B-ALL completed in July 2025; on track to launch pivotal Phase 2 in H2 2025 Servier arbitration: arbitral decision expected to be rendered on or before December 15, 2025 eti-cel (UCART20x22): Phase 1 study in r/r NHL...
Nasdaq GlobeNewswire
04/08/2025
PolTREG Doses First Patient in Phase II Trial for Pre-Symptomatic Type 1…
PolTREG Doses First Patient inPhase II Trial for Pre-Symptomatic Type 1 Diabetes with PTG-007 PTG-007, an autologous cell therapy will be administered to 150 high-risk children aged 3–18, including a placebo-controlled arm.A parallel study presented to FDA and to be conducted by Immuthera has been received favorably, may include Polish patients in the U.S. Statistical analysis, and could be treated as pivotal. The project has received an $11.3 million non-dilutive grant...
Nasdaq GlobeNewswire
04/08/2025
Microbiome Sequencing Market on the Rise: 19.3% CAGR Forecast
The report offers a detailed analysis of the microbiome sequencing market, segmented by component, sequencing technology, laboratory type, application, and end user. It explores trends, market drivers, restraints, and opportunities, while also examining macroeconomic influences, regulatory frameworks, technological advances, and ESG initiative. The study offers insights into the competitive landscape and profiles of leading companies. Regional coverage spans North America, Europe, Asia-Pacific…
PR Newswire
04/08/2025
First-Ever Comparative Study of Hypothermic Oxygenated Machine Perfusion (HOPE)…
The results of the study were presented by Chase J. Wehrle, MD, Cleveland Clinic Transplant Center, Cleveland, Ohio, at a Plenary Presentation Podium Session, and was designated a Young Investigators Award Winner. The analysis utilized data from the 12-month follow-up study of the Bridge to Life Ltd. Bridge to Hope clinical trial (HOPE with VitaSmart® Machine Perfusion System). The results of the study were presented byChase J. Wehrle, MD, Cleveland Clinic Transplant Center,Cleveland, Ohio...
PR Newswire
04/08/2025
Altri Comunicati
